Latest News
Haisco receives US FDA approval for anaesthetic Cipepofol
...
Anixa secures Canadian patent milestone for ovarian cancer vaccine
1 June 2026 - Biotechnology company Anixa Biosciences Inc (NASDAQ: ANIX) reported on Monday that it has received a Notice of Allowance from the Canadian Intellectual Property Office for a patent covering key aspects of its ovarian cancer vaccine tech...
hVIVO secures Decoy Therapeutics consultancy contract for antiviral development
1 June 2026 - Clinical development partner hVIVO plc (AIM: HVO) announced on Monday that it has signed a consultancy agreement with Decoy Therapeutics to support the development of its respiratory antiviral portfolio, positioning the programmes for p...
AstraZeneca reports trial results showing immunotherapy combinations reduce progression risk in liver cancer
1 June 2026 - Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) on Monday reported positive results from the EMERALD-3 Phase III trial evaluating IMFINZI (durvalumab) in combination with IMJUDO (tremelimumab-actl), lenvatinib a...
Rallybio and Avenzo Therapeutics announce merger agreement and USD215m financing
1 June 2026 - Clinical-stage biotechnology companies Rallybio Corporation (Nasdaq:RLYB) and Avenzo Therapeutics Inc announced on Monday that they have entered into a definitive merger agreement under which Rallybio will acquire Avenzo, with the combi...